晨光生物(300138.SZ)擬與華裕永誠合作投建大蒜脱水加工項目
格隆匯11月20日丨晨光生物(300138.SZ)公佈,公司第四屆董事會第十二次會議審議通過了《關於合作投建大蒜脱水加工項目的議案》。為充分利用公司在天然植物提取技術方面的優勢,本着惠農利農、資源綜合利用的原則,公司擬與河北華裕永誠食品有限公司(“華裕永誠”)合作投建大蒜脱水加工項目,並新設合資公司負責該項目的具體運營。合資公司擬註冊資本為1000萬元人民幣,雙方各出資500萬元人民幣,各持有50%股份。
合資公司計劃建設10條脱水大蒜加工生產線、污水處理系統、大蒜素提取車間等(分期投建),致力打造一個現代化大蒜脱水加工、大蒜素和大蒜多糖提取的高科技現代農業開發加工項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.